The Deal) -- Belgium's UCB is putting Kremers Urban Pharmaceuticals back on the auction block after the collapse of the agreed $1.53 billion sale of the Princeton, N.J.-based generics business to Advent International and Avista Capital...
Weeks after Belgium's UCB announced that it would sell its U.S. generic drug business for $1.53 billion, the company is calling off the sale in light of regulatory pushback over one of the unit's products.
Belgian drugmaker UCB SA announced an agreement Friday, Nov. 7, to sell Princeton, N.J.-based generics maker Kremers Urban Pharmaceuticals Inc. to buyout shops Advent International Corp. and Avista Capital Partners for $1.53 billion.
IMS Health (NYSE: IMS) today announced that it has entered into an innovative collaboration with UCB to help deliver greater business insights and improved operations, leveraging IMS Health's Nexxus™ Commercial Application Suite and the IMS...
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Amgen+%28AMGN%29%2C+UCB+Present+Data+from+Romosozumab+Phase+2+in+Postmenopausal+Women+with+Low+BMD/9832979.html for the full story.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to UCB SA (UCB-BT):